Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2025 |
|---|---|
| Revenue | — |
| R&D expense | $537.7M |
| Operating income | −$1.09B |
| Net income | −$1.08B |
| Cash & equivalents | $225.3M |
| Total debt | $20.9M |
| Operating cash flow | −$322.9M |
| Free cash flow | −$323.6M |
Company profile
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.